TuisABUS • NASDAQ
add
Arbutus Biopharma Corp
Vorige sluiting
$4,90
Dagwisseling
$4,45 - $4,89
Jaarwisseling
$2,71 - $5,10
Markkapitalisasie
854,98 m USD
Gemiddelde volume
1,23 m
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Jun. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 10,74 m | 522,19% |
Bedryfskoste | 8,45 m | -61,55% |
Netto inkomste | 2,52 m | 112,74% |
Netto winsgrens | 23,49 | 102,05% |
Wins per aandeel | 0,01 | 109,05% |
EBITDA | 1,92 m | 109,15% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Jun. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 98,09 m | -30,92% |
Totale bates | 103,27 m | -35,48% |
Totale aanspreeklikheid | 20,29 m | -46,02% |
Totale ekwiteit | 82,98 m | — |
Uitstaande aandele | 191,70 m | — |
Prys om te bespreek | 11,40 | — |
Opbrengs op bates | 4,34% | — |
Opbrengs op kapitaal | 5,54% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Jun. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 2,52 m | 112,74% |
Kontant van bedrywe | -15,75 m | -8,58% |
Kontant van beleggings | 15,61 m | 58,83% |
Kontant van finansiering | 453,00 k | -98,14% |
Netto kontantverandering | 336,00 k | -98,29% |
Beskikbare kontantvloei | -13,34 m | -87,90% |
Meer oor
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. Wikipedia
Gestig
2007
Webwerf
Werknemers
44
